伊伐布雷定

{{Infobox drug
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 477495852
| image = Ivabradine Structural Formula V.1.svg
| image_class = skin-invert-image
| width = 200
| alt =
| image2 = Ivabradine-based-on-xtal-3D-bs-17.png
| image_class2 = bg-transparent
| width2 = 200
| alt2 =

| pronounce =
| tradename = Corlanor, Procoralan 等
| Drugs.com =
| MedlinePlus = a615027
| DailyMedID = Ivabradine
| pregnancy_AU =
| pregnancy_AU_comment =
| pregnancy_category=
| routes_of_administration = 口服
| class =
| ATC_prefix = C01
| ATC_suffix = EB17
| ATC_supplemental = ,

| legal_AU =
| legal_AU_comment =
| legal_BR =
| legal_BR_comment =
| legal_CA = Rx-only
| legal_CA_comment =

| legal_DE =
| legal_DE_comment =
| legal_NZ =
| legal_NZ_comment =
| legal_UK = POM
| legal_UK_comment =
| legal_US = Rx-only
| legal_US_comment =
| legal_EU = Rx-only
| legal_EU_comment =
| legal_UN =
| legal_UN_comment =
| legal_status =

| bioavailability = 40%
| protein_bound = 70%
| metabolism = 肝臟（首渡效應）>50%，經CYP3A4代謝
| elimination_half-life = 6 小時
| excretion = 及糞便

| CAS_number_Ref =
| CAS_number = 155974-00-8
| CAS_supplemental =
| PubChem = 132999
| IUPHAR_ligand = 2357
| DrugBank_Ref =
| DrugBank = DB09083
| ChemSpiderID_Ref =
| ChemSpiderID = 117373
| UNII_Ref =
| UNII = 3H48L0LPZQ
| KEGG_Ref =
| KEGG = D07165
| ChEBI_Ref =
| ChEBI = 85966
| ChEMBL_Ref =
| ChEMBL = 471737
| NIAID_ChemDB =
| PDB_ligand =
| synonyms = S-16257

| IUPAC_name = 3-[3-({[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino)propyl]-7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepin-2-one
| C=27 | H=36 | N=2 | O=5
| SMILES = O=C2N(CCc1cc(OC)c(OC)cc1C2)CCCN(C[C@@H]4c3cc(OC)c(OC)cc3C4)C
| StdInChI_Ref =
| StdInChI = 1S/C27H36N2O5/c1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30/h12-14,16,21H,6-11,15,17H2,1-5H3/t21-/m1/s1
| StdInChIKey_Ref =
| StdInChIKey = ACRHBAYQBXXRTO-OAQYLSRUSA-N
}}

伊伐布雷定（INN：）是一種（, If）抑制劑，用於心絞痛及心臟衰竭的症狀控制的治療藥物。伊伐布雷定的適合症，需符合以下條件：有症狀的心臟衰竭、左心室射出分率降低、心率至少每分鐘70下，且症狀無法單獨以β受體阻斷劑充分控制。

伊伐布雷定透過抑制竇房結的產生負性變時作用（），而降低心率。它的作用機轉與β受體阻斷劑及鈣通道阻斷劑不同，後兩者為臨床上常見的抗心絞痛藥物類別。伊伐布雷定不具明顯的正性肌力作用（），雖然無法增強心肌收縮力，但能改善心臟功能，因此也可能屬於強心劑（）之一。

參考文獻
外部連結